Upregulation of the chemokine receptor CCR2B in Epstein-Barr Virus-positive Burkitt lymphoma cell lines with the latency III program

Svetlana Kozireva, Zhanna Rudevica, Mikhail Baryshev, Ainars Leonciks, Elena Kashuba, Irina Kholodnyuk (Coresponding Author)

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
1 Downloads (Pure)

Abstract

CCR2 is the cognate receptor to the chemokine CCL2. CCR2–CCL2 signaling mediates cancer progression and metastasis dissemination. However, the role of CCR2–CCL2 signaling in pathogenesis of B-cell malignancies is not clear. Previously, we showed that CCR2B was upregulated in ex vivo peripheral blood B cells upon Epstein-Barr virus (EBV) infection and in established lymphoblastoid cell lines with the EBV latency III program. EBV latency III is associated with B-cell lymphomas in immunosuppressed patients. The majority of EBV-positive Burkitt lymphoma (BL) tumors are characterized by latency I, but the BL cell lines drift towards latency III during in vitro culture. In this study, the CCR2A and CCR2B expression was assessed in the isogenic EBV-positive BL cell lines with latency I and III using RT-PCR, immunoblotting, and immunostaining analyses. We found that CCR2B is upregulated in the EBV-positive BL cells with latency III. Consequently, we detected the migration of latency III cells toward CCL2. Notably, the G190A mutation, corresponding to SNP CCR2-V64I, was found in one latency III cell line with a reduced migratory response to CCL2. The upregulation of CCR2B may contribute to the enhanced migration of malignant B cells into CCL2-rich compartments.

Original languageEnglish
Article number239
JournalViruses
Volume10
Issue number5
DOIs
Publication statusPublished - 3 May 2018

Keywords

  • B-cell lymphoma
  • Burkitt lymphoma cell lines
  • CCR2
  • EBV
  • Latency III

Field of Science

  • 3.2 Clinical medicine

Publication Type

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Upregulation of the chemokine receptor CCR2B in Epstein-Barr Virus-positive Burkitt lymphoma cell lines with the latency III program'. Together they form a unique fingerprint.

Cite this